Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (


PURPOSE:Patients with large prostate glands are underrepresented in clinical trials incorporating brachytherapy due to concerns for excessive toxicity. We sought to compare health-related quality of life (HRQOL) outcomes between small (<60 cc) and large (≥60 cc) prostates treated with high-dose-rate brachytherapy (HDR-B). METHODS AND MATERIALS:One hundred thirty patients at Emory University were treated with HDR-B monotherapy (n = 75) or HDR-B in combination with external beam radiation therapy (n = 55). American Urologic Association Symptom Score (AUASS) and expanded prostate cancer index composite for clinical practice (EPIC-CP) scores were recorded. A linear mixed model was performed dichotomizing prostate volume (<60 and ≥ 60 cc) with AUASS, individual EPIC-CP domains (urinary incontinence, urinary irritation/obstruction [UIO], bowel function, sexual function, and vitality/hormonal function), and overall EPIC-CP HRQOL scores. RESULTS:Median followup was 22.6 months (range 2.2-55.8). The median gland volume for the entire cohort (n = 130), <60 cc cohort (n = 104), and ≥60 cc cohort (n = 26) was 44 cc, 41.1 cc, and 68.0 cc, respectively. There were no baseline differences in HRQOL scores between cohorts. At 2 months, AUASS and UIO scores increased similarly between cohorts (AUASS p = 0.807; UIO p = 0.539), then decreased (longitudinal effect p < 0.001 and p = 0.005, respectively) to remain not significantly different at 12 months (AUASS p = 0.595; UIO p = 0.673). Overall, prostate volume was not significantly associated with change in AUASS (p = 0.403), urinary incontinence (p = 0.322), UIO symptoms (p = 0.779), bowel symptoms (p = 0.757), vitality/hormonal symptoms (p = 0.503), or overall HRQOL (p = 0.382). CONCLUSIONS:In appropriately selected patients, HDR-B appears well tolerated in patients with ≥60 cc prostate glands without an increase in patient-reported toxicity. Volume should not be a strict contraindication in those with adequate baseline function.






Press RH,Morgan TM,Cutrell PK,Zhang C,Chen Z,Rahnema S,Sanda M,Pattaras J,Patel P,Jani AB,Rossi PJ




Has Abstract


2019-01-01 00:00:00














  • MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy.

    abstract:PURPOSE:We sought to develop an activity nomogram for magnetic resonance (MR)-planned permanent seed prostate brachytherapy to improve quality assurance through a secondary dosimetric check. METHODS AND MATERIALS:Patients undergoing MRI-assisted radiosurgery (MARS), whereby MRI is used for preoperative planning and po...


    pub_type: 杂志文章


    authors: Hanania AN,Kudchadker RJ,Bruno TL,Tang C,Anscher MS,Frank SJ

    更新日期:2020-01-01 00:00:00

  • Improving the treatment planning and delivery process of Xoft electronic skin brachytherapy.

    abstract:PURPOSE:To develop an improved Xoft electronic skin brachytherapy process and identify areas of further improvement. METHODS AND MATERIALS:A multidisciplinary team conducted a failure modes and effects analysis (FMEA) by developing a process map and a corresponding list of failure modes. The failure modes were scored ...


    pub_type: 杂志文章


    authors: Manger R,Rahn D,Hoisak J,Dragojević I

    更新日期:2018-01-01 00:00:00

  • Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry.

    abstract:PURPOSE:The study aimed to analyze the Pro-Qura database in terms of patient implant sequence number for each institution to determine evidence for a dosimetric learning curve. METHODS AND MATERIALS:In the Pro-Qura database, 2833 of a total of 4614 postplans from 57 brachytherapists were analyzed for evidence of a dos...


    pub_type: 杂志文章


    authors: Merrick GS,Grimm PD,Sylvester J,Blasko JC,Butler WM,Allen ZA,Chaudhry UU,Mazza A,Sitter M

    更新日期:2007-01-01 00:00:00

  • Monte Carlo calculation of the dose perturbations in a dual-source HDR/PDR afterloader treatment unit.

    abstract:PURPOSE:Currently, there are high dose rate afterloaders available that can drive two different radioactive sources simultaneously. The source-source and source-cable attenuations are not taken into account by current planning systems. The purpose of this work is to characterize these effects and their overall impact o...


    pub_type: 杂志文章


    authors: Collins-Fekete CA,Plamondon M,Verhaegen F,Beaulieu L

    更新日期:2016-07-01 00:00:00

  • Intravascular brachytherapy using 90Sr for saphenous vein grafts having diameters ranging from 2.0-5.0 mm.

    abstract:PURPOSE:Symptomatic coronary artery disease is routinely treated with angioplasty and stenting. Unfortunately, treatment failure in the form of in-stent restenosis (ISR) occurs relatively frequently. Intravascular brachytherapy (IVBT) is a safe and effective method proven to markedly reduce the rate of ISR in native co...


    pub_type: 杂志文章


    authors: Mignano JE,Rivard MJ

    更新日期:2004-01-01 00:00:00

  • Locally advanced cervical cancer in renal transplant patients: a dilemma between control and toxicity.

    abstract:PURPOSE:Treatment of locally advanced cervical cancer in patients with a renal graft requires precautions. The graft is usually in a pelvic position, close to the clinical target volume (CTV). Preserving the graft while ensuring local control is a challenge we have faced in two occasions. We report our experience. MET...


    pub_type: 社论


    authors: Maroun P,Rivin E,Dumas I,Mondini M,Brahim J,Haie-Meder C,Mazeron R

    更新日期:2014-01-01 00:00:00

  • Changes in brachytherapy-based APBI patient selection immediately before and after publication of the ASTRO consensus statement.

    abstract:PURPOSE:In July 2009, American Society of Radiation Oncology (ASTRO) released a consensus statement (CS) to guide patient selection for accelerated partial breast irradiation (APBI). The goal of this study was to examine how practice patterns changed following the guideline's release. METHODS:The Surveillance, Epidemi...


    pub_type: 杂志文章


    authors: Husain ZA,Lloyd S,Shah C,Wilson LD,Koshy M,Mahmood U

    更新日期:2015-07-01 00:00:00

  • Palliative treatment by high-dose-rate intraluminal brachytherapy in patients with advanced esophageal cancer.

    abstract:PURPOSE:The aim of this work was to analyze the results of palliative HDR brachytherapy in patients with advanced esophageal cancer. METHODS AND MATERIALS:Ninety-one patients with unresectable, advanced esophageal cancer were treated palliatively by HDR brachytherapy. All patients received a total dose of 22.5 Gy in t...


    pub_type: 临床试验,杂志文章


    authors: Skowronek J,Piotrowski T,Zwierzchowski G

    更新日期:2004-01-01 00:00:00

  • MammoSite accelerated partial breast irradiation: a single-institution outcomes analysis with 2 years of followup.

    abstract:PURPOSE:To provide longitudinal follow-up and assess the intermediate outcomes in breast cancer patients treated with the MammoSite radiation therapy system. METHODS AND MATERIAL:Ninety-two patients with histologically proven stage 0-II breast cancer were treated with MammoSite accelerated partial breast irradiation a...


    pub_type: 杂志文章


    authors: Haley M,Beriwal S,Heron DE,Kim H,Falk J,Johnson R,Mogus R

    更新日期:2009-01-01 00:00:00

  • Measuring relief of dysphagia in locally advanced esophageal carcinoma patients submitted to high-dose-rate brachytherapy.

    abstract:BACKGROUND AND PURPOSE:Esophageal neoplasm has a poor prognosis, and palliative care remains an important goal of treatment. The purpose of this study was to assess the ability of high-dose-rate brachytherapy (HDRB) to improve dysphagia in 115 patients treated at our institution. METHODS AND MATERIALS:Patients previou...


    pub_type: 杂志文章


    authors: Grazziotin Reisner R,Reisner ML,Ferreira MA,Rosa AA,Veras IM,Carneiro TM,Wolff B,Viégas CM,Mendonça de Araújo CM,Marchiori E

    更新日期:2015-01-01 00:00:00

  • Californium-252 neutron brachytherapy combined with external beam radiotherapy for esophageal cancer: long-term treatment results.

    abstract:PURPOSE:The aim of this study was to retrospectively observe and analyze the long-term treatment outcomes for a total of 952 esophageal cancer patients who were treated with (252)Cf neutron brachytherapy (NBT) in combination with external beam radiotherapy (EBRT). METHODS AND MATERIALS:From November 2001 to March 2012...


    pub_type: 杂志文章


    authors: Liu H,Wang Q,Wan X,Jia X,Liu B,Wang CK

    更新日期:2014-09-01 00:00:00

  • Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program.

    abstract:PURPOSE:To describe in detail British Columbia (BC) Cancer Agency (BCCA) Provincial Prostate Brachytherapy (PB) Quality Assurance (QA) Program. METHODS AND MATERIALS:The BCCA PB Program was established in 1997. It operates as one system, unified and supported by electronic and information systems, making it a single P...


    pub_type: 杂志文章


    authors: Keyes M,Morris WJ,Spadinger I,Araujo C,Cheung A,Chng N,Crook J,Halperin R,Lapointe V,Miller S,Pai H,Pickles T

    更新日期:2013-07-01 00:00:00

  • Transition from LDR to HDR brachytherapy for cervical cancer: Evaluation of tumor control, survival, and toxicity.

    abstract:PURPOSE:In 2012, our institution transitioned from low-dose-rate (LDR) brachytherapy to high dose-rate (HDR) brachytherapy. We report clinical outcomes after brachytherapy for cervical cancer at our institution over a continuous 10-year period. METHODS AND MATERIALS:From 2004 to 2014, 258 women (184 LDR and 74 HDR) we...


    pub_type: 杂志文章


    authors: Romano KD,Pugh KJ,Trifiletti DM,Libby B,Showalter TN

    更新日期:2017-01-01 00:00:00

  • The effect of obesity on rectal dosimetry after permanent prostate brachytherapy.

    abstract:OBJECTIVES:Men with higher body mass index (BMI) tend to have more fatty tissue in prostate-rectum interface, which may reduce the rectal wall dose by the inverse square law. We hypothesized that men with higher BMI will have a lower dose to the rectal wall and less rectal toxicity after permanent prostate implant. ME...


    pub_type: 杂志文章


    authors: Patil N,Crook J,Saibishkumar EP,Aneja M,Borg J,Pond G,Ma C

    更新日期:2009-04-01 00:00:00

  • Simulation analysis of optimized brachytherapy for uterine cervical cancer: Can we select the best brachytherapy modality depending on tumor size?

    abstract:PURPOSE:To choose the optimal brachytherapeutic modality for uterine cervical cancer, we performed simulation analysis. METHODS AND MATERIALS:For each high-risk clinical target volume (HR CTV), we compared four modalities [classical conventional intracavitary brachytherapy (ConvICBT), Image-guided ICBT (IGICBT), intra...


    pub_type: 杂志文章


    authors: Yoshida K,Yamazaki H,Kotsuma T,Takenaka T,Ueda MM,Miyake S,Tsujimoto Y,Masui K,Yoshioka Y,Sumida I,Uesugi Y,Shimbo T,Yoshikawa N,Yoshioka H,Tanaka E,Narumi Y

    更新日期:2016-01-01 00:00:00

  • Postmortem radiation safety and issues pertaining to permanent prostate seed implantation in Japan.

    abstract:PURPOSE:If a prostate cancer patient treated with (125)I brachytherapy dies within 12 months after the treatment, prostate removal before cremation is recommended to avoid problems related to radioactivity in the ashes, such as inhalation of airborne particulate matter by crematorium staff or nearby residents. To provi...


    pub_type: 杂志文章,评审


    authors: Satoh T,Dokiya T,Yamanaka H,Saito S,Ishiyama H,Itami J,Shibuya H,Nakano T,Shigematsu N,Aoki M,Egawa S,Hashimoto M,Nishimura T,Yorozu A

    更新日期:2015-03-01 00:00:00

  • Reirradiation of paraaortic lymph node metastasis by brachytherapy with hyaluronate injection via paravertebral approach: With DVH comparison to IMRT.

    abstract:UNLABELLED:PURPOSE/INTRODUCTION: To safely irradiate retroperitoneal targets as paraaortic lymph node by separating abdominal at-risk organs from the target during irradiation, we created a percutaneous paravertebral approach of high-dose-rate brachytherapy with hyaluronate gel injection (HGI). We report a case treated...


    pub_type: 杂志文章


    authors: Kishi K,Sonomura T,Shirai S,Noda Y,Sato M,Ikushima H,Oh RJ

    更新日期:2013-01-01 00:00:00

  • Breast conservation surgery and interstitial brachytherapy in the management of locally recurrent carcinoma of the breast: the Allegheny General Hospital experience.

    abstract:PURPOSE:To evaluate lumpectomy followed by interstitial brachytherapy as an acceptable salvage therapy for women who have developed localized recurrence of breast cancer after conservation surgery and postoperative external radiotherapy. METHODS AND MATERIALS:Between 1/1998 and 10/2006, 21 patients with T0 or T1 in-br...


    pub_type: 杂志文章


    authors: Trombetta M,Julian T,Bhandari T,Werts ED,Miften M,Parda D

    更新日期:2008-01-01 00:00:00

  • Rectal spacing, prostate coverage, and periprocedural outcomes after hydrogel spacer injection during low-dose-rate brachytherapy implantation.

    abstract:PURPOSE:To analyze the dosimetric impact and periprocedural outcomes with a bioabsorbable hydrogel rectal spacer injected during low-dose-rate (LDR) prostate brachytherapy implants. METHODS AND MATERIALS:A consecutive series of 80 patients implanted with stranded I-125 LDR brachytherapy seeds were evaluated, of which ...


    pub_type: 杂志文章


    authors: Kahn J,Dahman B,McLaughlin C,Kapoor P,Kapoor R,Harris E,Sharma M,Schutzer M,Moghanaki D

    更新日期:2020-01-01 00:00:00

  • Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: outcome and toxicity.

    abstract:OBJECTIVES:To evaluate the interim outcomes of low-dose-rate permanent brachytherapy (PB) combined with short-term androgen deprivation therapy (ADT) in Japanese men with intermediate-risk prostate cancer excluding those with a Gleason score of 4+3. METHODS:The Protocol-intermediate-risk group (Protocol-IRG) was defin...


    pub_type: 杂志文章


    authors: Yamada Y,Masui K,Iwata T,Naitoh Y,Yamada K,Miki T,Okihara K

    更新日期:2015-03-01 00:00:00

  • Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy.

    abstract:PURPOSE:To validate the 2019 NCCN subgroups of favorable- and unfavorable-intermediate risk (IR) prostate cancer among patients treated with brachytherapy, who are underrepresented in the studies used to develop the 2019 NCCN classification. METHODS:We included all 2,705 men treated with I-125 LDR brachytherapy monoth...


    pub_type: 杂志文章


    authors: Tom MC,Reddy CA,Smile TD,Zhang RX,Ciezki JP,Stephans KL,Mian OY,Klein EA,Campbell S,Ulchaker J,Angermeier K,Tendulkar RD

    更新日期:2020-01-01 00:00:00

  • Two-year results of transabdominal ultrasound-guided brachytherapy for cervical cancer.

    abstract:PURPOSE:To report the preliminary results of transabdominal ultrasound (TAUS)-guided brachytherapy (BT) in cervical cancer. METHODS AND MATERIALS:Twenty-nine patients with cervical cancer Stage IB-IVA according to The International Federation of Gynecology and Obstetrics staging were treated by radical radiotherapy fr...


    pub_type: 杂志文章


    authors: Tharavichitkul E,Tippanya D,Jayavasti R,Chakrabandhu S,Klunklin P,Onchan W,Wanwilairat S,Galalae RM,Chitapanarux I

    更新日期:2015-03-01 00:00:00

  • Review of brachytherapy complications - Upper gastrointestinal tract.

    abstract::While brachytherapy applications are not widely used for cancer diagnoses in the upper GI tract (including the esophagus, liver, stomach, and pancreas), they have a clear role in palliation and symptom management and occasionally definitive locoregional treatment. With the increasing use of image-guided techniques, th...


    pub_type: 杂志文章,评审


    authors: Folkert MR,Gottumukkala S,Nguyen NT,Taggar A,Sur RK

    更新日期:2020-12-22 00:00:00

  • Evaluation of a collapsed-cone convolution algorithm for esophagus and surface mold 192Ir brachytherapy treatment planning.

    abstract:PURPOSE:TG43 does not account for a lack of scatter and tissue and applicator heterogeneities. The advanced collapsed-cone engine (ACE) algorithm available for use in the Oncentra Brachy treatment planning system (Elekta AB, Stockholm, Sweden) can model these conditions more accurately and is evaluated for esophageal a...


    pub_type: 杂志文章


    authors: Eason L,Mason J,Cooper R,Radhakrishna G,Bownes P

    更新日期:2020-10-15 00:00:00

  • A linear source table to determine the treatment times for cylindrical applicators used in high-dose rate brachytherapy.

    abstract:PURPOSE:It is a good practice for quality assurance purposes to check the high-dose rate brachytherapy source dwell times obtained from any computerized treatment planning system (TPS) by independent hand calculations. The aim of this work was to prepare a table that would help to calculate the total dwell times for cy...


    pub_type: 杂志文章


    authors: Sha RL,Reddy PY,Sahoo N

    更新日期:2011-05-01 00:00:00

  • American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer.

    abstract:PURPOSE:To present recommendations for the use of interstitial brachytherapy in patients with vaginal cancer or recurrent endometrial cancer in the vagina. METHODS:A panel of members of the American Brachytherapy Society reviewed the literature, supplemented that with their clinical experience, and formulated recommen...


    pub_type: 杂志文章,实务指引


    authors: Beriwal S,Demanes DJ,Erickson B,Jones E,De Los Santos JF,Cormack RA,Yashar C,Rownd JJ,Viswanathan AN,American Brachytherapy Society.

    更新日期:2012-01-01 00:00:00

  • Single-energy metal artifact reduction in postimplant computed tomography for I-125 prostate brachytherapy: Impact on seed identification.

    abstract:PURPOSE:To evaluate the effectiveness of the single-energy metal artifact reduction (SEMAR) technique for improving the accuracy of I-125 seed identification in postimplant computed tomography (CT) after prostate brachytherapy. METHODS AND MATERIALS:Postimplant CT images of 40 patients treated with I-125 prostate brac...


    pub_type: 杂志文章


    authors: Shiraishi Y,Yamada Y,Tanaka T,Eriguchi T,Nishimura S,Yoshida K,Hanada T,Ohashi T,Shigematsu N,Jinzaki M

    更新日期:2016-01-01 00:00:00

  • Patient-reported sexual adjustment after definitive chemoradiation and MR-guided brachytherapy for cervical cancer.

    abstract:PURPOSE:The treatment of locally advanced cervical cancer with definitive chemoradiation (CRT) is associated with vaginal toxicity and altered sexual satisfaction. This prospective study assessed patient-reported sexual adjustment, vaginal dosimetry, and physician-reported vaginal toxicity in patients with cervical can...


    pub_type: 杂志文章


    authors: Conway JL,Gerber R,Han K,Jiang H,Xie J,Beiki-Ardakani A,Fyles A,Milosevic M,Williamson D,Croke J

    更新日期:2019-01-01 00:00:00

  • Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.

    abstract:PURPOSE:To identify patients at extremely low risk of biochemical recurrence (BCR) of prostate cancer after low-dose-rate brachytherapy (LDR-BT) to determine when prostate-specific antigen (PSA) monitoring can be stopped. METHODS AND MATERIALS:We retrospectively reviewed clinicopathologic data of patients with prostat...


    pub_type: 杂志文章


    authors: Niwa N,Matsumoto K,Nishiyama T,Yagi Y,Ozu C,Nakamura K,Saito S,Oya M

    更新日期:2018-01-01 00:00:00

  • Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer.

    abstract:PURPOSE:To evaluate the efficacy and side effect profile of adjuvant vaginal vault brachytherapy alone after hysterectomy in Stage I endometrial carcinoma. METHODS AND MATERIALS:Between 23/11/1992 and 16/05/2005, a total of 173 patients with early endometrial carcinoma treated with vaginal vault brachytherapy alone po...


    pub_type: 杂志文章


    authors: Chong I,Hoskin PJ

    更新日期:2008-04-01 00:00:00